Amgen Q3 2024 Adj EPS $5.58 Beats $5.11 Estimate, Sales $8.50B Miss $8.52B Estimate
Portfolio Pulse from Benzinga Newsdesk
Amgen reported Q3 2024 earnings with an adjusted EPS of $5.58, surpassing the estimate of $5.11. However, sales were slightly below expectations at $8.50 billion, missing the $8.52 billion estimate. Sales increased by 23.18% compared to the same period last year.
October 30, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's Q3 2024 earnings per share exceeded expectations, but sales slightly missed estimates. Despite the sales miss, the significant year-over-year sales growth is a positive indicator.
Amgen's earnings per share exceeded analyst expectations by 9.2%, which is a strong positive signal for investors. Although sales were slightly below estimates, the year-over-year growth of 23.18% is impressive. The positive earnings surprise is likely to have a favorable impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100